Announced Date: 2025-01-02 (January 2, 2025)
Asset Name: IBI3009
Licensor: Innovent (Innovent Biologics, Inc.，China)
Licensee (Buyer): Roche
.
Asset Modality: ADC (antibody drug conjugate)
Asset Target: DLL3
Potential Indication: small cell lung cancer
Current Stage: Phase 1
.
Scope of Authority:
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009.
The two parties will jointly focus on the early-stage development of this ADC candidate, after which Roche will take over full development.
.
Deal Detail:
Upfront payment of $80 million,
Milestone payments up to $1 billion.
Tiered royalties on net sales.
.
Link:
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=499
